Principal IT Infrastructure Engineer
Liquidia
Principal IT Infrastructure Engineer
Liquidia
Clinical-stage biopharma developing PRINT-based therapeutics
Liquidia uses PRINT particle engineering to design drug particles that can improve safety, efficacy, and manufacturability. Its two main candidates are LIQ861 for pulmonary arterial hypertension and LIQ865 for local post-operative pain, developed through clinical testing toward commercialization. The technology controls particle size and properties to enhance delivery and performance while aiming to reduce production complexity and cost. By tailoring particle delivery for specific conditions, Liquidia pursues regulatory approvals to bring products to market and generates revenue from sales, supported by stock offerings for funding.
Explore more opportunities at Liquidia